Outbreak of *Fusarium oxysporum* infections in children with cancer: an experience with 7 episodes of catheter-related fungemia

Fabianne Carlesse¹,², Anna-Paula C. Amaral², Sarah S. Gonçalves³, Hemilio Xafranski³, Maria-Lucia M. Lee¹, Victor Zecchin¹, Antonio S. Petrilli¹, Abdullah M. Al-Hatmi⁴,⁵, Ferry Hagen⁶, Jacques F. Meis⁵,⁶ and Arnaldo L. Colombo³*

**Abstract**

*Background:* *Fusarium* species are widely spread in nature as plant pathogens but are also able to cause opportunistic fungal infections in humans. We report a cluster of *Fusarium oxysporum* bloodstream infections in a single pediatric cancer center.

*Methods:* All clinical and epidemiological data related to an outbreak involving seven cases of fungemia by *Fusarium oxysporum* during October 2013 and February 2014 were analysed. All cultured isolates (*n* = 14) were identified to species level by sequencing of the TEF1 and RPB2 genes. Genotyping of the outbreak isolates was performed by amplified fragment length polymorphism fingerprinting.

*Results:* In a 5-month period 7 febrile pediatric cancer patients were diagnosed with catheter-related *Fusarium oxysporum* bloodstream infections. In a time span of 11 years, only 6 other infections due to *Fusarium* were documented and all were caused by a different species, *Fusarium solani*. None of the pediatric cancer patients had neutropenia at the time of diagnosis and all became febrile within two days after catheter manipulation in a specially designed room. Extensive environmental sampling in this room and the hospital did not give a clue to the source. The outbreak was terminated after implementation of a multidisciplinary central line insertion care bundle. All *Fusarium* strains from blood and catheter tips were genetically related by amplified fragment length polymorphism fingerprinting. All patients survived the infection after prompt catheter removal and antifungal therapy.

*Conclusion:* A cluster with, genotypical identical, *Fusarium oxysporum* strains infecting 7 children with cancer, was most probably catheter-related. The environmental source was not discovered but strict infection control measures and catheter care terminated the outbreak.

*Keywords:* Fusariosis, *Fusarium* sp., *Fusarium oxysporum*, Catheter-related *Fusarium* fungemia, Pediatric invasive fungal infections

*Correspondence: arnaldolcolombo@gmail.com*

¹Division of Infectious Diseases, Escola Paulista de Medicina, Federal University of Sao Paulo (UNIFESP), Rua Pedro de Toledo, 669 e 5º-andar, Sao Paulo CEP 04039-032, Brazil

Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
**Background**

Due to prolonged survival of patients with cancer, invasive fungal diseases (IFD) emerged as important cause of morbidity and mortality. In pediatric cancer patients, *Candida* species remain as the most important cause of IFD followed by invasive infections by *Aspergillus* spp. and other moulds [1–3].

Epidemiology of fungal infections varies markedly according to the geographic region. In Brazil, *Fusarium* spp. infections have emerged as major pathogens of systemic infections among cancer patients [4]. *Fusarium* species are widely spread in nature as plant pathogens and are also able to cause superficial, locally invasive and disseminated infections in humans [5]. Infection occurs mainly through airborne transmission, skin breakdown due to trauma, burns or insertion of vascular catheters [6, 7]. The clinical presentation relies mostly on the hosts’ immune status, with disseminated infections been reported especially in severe immunocompromised individuals leading to high mortality rates [6, 8].

The lack of data concerning the epidemiology and clinical aspects of invasive infections by *Fusarium* spp. in pediatric patients is notable. Here we report a cluster of *Fusarium oxysporum* bloodstream infections from seven pediatric cancer patients documented in a single Brazilian pediatric cancer center.

**Methods**

We retrospectively studied all clinical and epidemiological data related to an outbreak enrolling seven cases of fungemia by *Fusarium oxysporum* occurring between October 2013 and February 2014 in the Pediatric Oncology Institute (IOP), located in Sao Paulo, Brazil. IOP is a tertiary care hospital specialized in pediatric oncology which admits 300 new cases per year. The outbreak was documented in patients who had been treated with chemotherapy at the same room used for cancer ambulatory chemotherapy. All long-term intravascular catheters are implanted in the surgery room and cared for by a group of trained nurses.

Clinical and epidemiological data were collected by a single investigator who reviewed all electronic medical records in order to complete a clinical form including information related to gender, age, underlying diseases, presence of neutropenia, exposition to invasive medical procedures and immunosuppressive drugs, imaging, culture results, treatment and clinical outcome.

During the outbreak, all catheters were removed and cultured in accordance with procedures standardized in our division based on cultures of catheter tips and material inside the reservoir. A cut-off of ≥10^3 CFU/plate was used to differentiate significant from insignificant colonization as suggested by Brun–Buisson et al. [9, 10]. All patients were screened for putative deep-seated infection by sinus and chest CT as well as echocardiography and eye fundoscopy. After the diagnosis of fusariosis, at least two serum samples were collected from each patient to check for galactomannan levels and patients were followed for another 90 days for clinical signs and symptoms.

**Laboratory procedures**

**Isolates**

All *Fusarium* spp. cultured from blood and catheter samples (swab, flush and tip) were initially identified by morphological characteristics [11] and further identified to species level by sequencing *TEF1* and *RPB2* genes [12].

Besides clinical strains, we cultured environmental samples including air-filters, tap water samples, swab of room surfaces, and different intravenously administered drugs [13, 14]. We finally also evaluated all health care workers for the presence of onychomycosis or other superficial fungal infections.

**Molecular identification of *Fusarium* isolates**

Genomic DNA of all *Fusarium* isolates was extracted with the PrepMan Ultra Sample Preparation Reagent kit (Applied Biosystems, Palo Alto, CA, USA) according to the manufacturer's instructions. PCRs were performed for the amplification of the largest subunit of RNA polymerase (*RPB2*) and the translation elongation factor-1α (*TEF1α*) following the methods published by Salah et al. [15]. The primer pairs for *TEF1α* were EF1 & EF2 [16] and for *RPB2* were RPB2-7cR & RPB2-5F [17]. PCR products were sequenced with the same primers used for amplification. The ABI Prism® Big DyeTM Terminator v. 3.0 Ready Reaction Cycle Sequencing Kit (Applied Biosystems) was used for sequencing PCR according to the manufacturer’s instructions. The samples were run on an ABI 3730XL automatic sequencer (Applied Biosystems). A BLAST search of *TEF1* and *RPB2* sequences against the database FUSARIUM-ID (http://isolate.fusariumdb.org/), the *Fusarium* database (http://www.cbs.knaw.nl/fusarium) and GenBank databases (www.ncbi.nlm.nih.gov) were used as an initial step to identify isolates to species and/or species complex. The *TEF1* and *RPB2* nucleotide sequences of all isolates were deposited in GenBank.

**Amplified fragment length polymorphism**

Amplified fragment length polymorphism (AFLP) fingerprinting was performed as described recently [18]. Briefly, ~50 ng of genomic DNA was digested by using the HpyCH4IV and Msel restriction enzymes (New England Biolabs, Ipswich, MA, U.S.A.) and in the same reaction specific adaptors were ligated to each of the two sticky ends of the DNA fragments. The samples were after a 1 h incubation at room temperature diluted with 10 mM Tris-HCl, 1.0 μl of this diluted product was used as input for the PCR that contains the selective primers HpyCH4IV-C (5’-Flu-
GTAGACTGCCTACCCGTAC-3’ and MseI-TGAG (5’-GATGAGTCCTGACTAATGAG). After the PCR was performed, the amplicons were 20× diluted using ddH2O and 1.0 μl of it was mixed with 8.9 μl ddH2O and 0.1 μl LIZ600 internal size marker (Promega, Leiden, The Netherlands) followed by a heating step for 1 min at 100 °C. Fragment analysis was performed on an ABI3500xL Genetic Analyzer (Applied Biosystems, Foster City, CA, U.S.A.) according to the manufacturer’s instructions. Subsequently, the raw data was imported into Bionumerics v7.5 (Applied Maths, Sint Martens-Latum, Belgium), after processing the data a dendrogram was generated by using the UPGMA algorithm.

Results
From October 2013 to February 2014 we were caught by surprise with the occurrence of seven episodes of microbiologic documented catheter-related *F. oxysporum* bloodstream infections (CR-BSI) in our division. This finding led us to believe that we were facing an outbreak because only six cases of invasive fusariosis had been diagnosed in our hospital in the 11 years previously, all caused by *Fusarium solani* species complex strains.

Demographic and clinical data of all seven patients are depicted in Table 1. Ages ranged from 0 to 8 years (3 males), 6 out 7 were treated with chemotherapy for solid tumors, and one for acute lymphoid leukemia (ALL). Two patients (solid tumors) had underwent an autologous stem cell transplantation more than 14 days before and none of the patients received corticosteroids or other immunosuppressive agents. Only one patient had a neutrophil count below 500 cells/mm³ at the moment of the infection. Fever was the only trigger to collect blood cultures and vascular catheters were removed promptly at the time fungemia was identified. The six intravascular devices removed included 5 totally surgically implanted (Porth-a-Cath) catheters and one peripherally inserted catheter (PICC). All fungemic episodes were documented following 2 days after the last catheter puncture by the nurse. No single patient had any additional skin breakdown or onychomycosis that could explain the portal of entrance for Fusarium spp. All catheter tips, reservoir and blood cultures collected through the CVC of the 7 patients yielded *Fusarium oxysporum*. Although they had no signs or symptoms of any organ involvement, further laboratorial investigation was conducted to exclude fungal invasion of target organs. All children had a chest computer tomography (CT), sinus magnetic resonance image, eye fundoscopy and echocardiography done without any evidence of a deep-seated fungal infection. All serum samples were galactomannan negative. Catheters were promptly removed after blood cultures became positive and all patients had good clinical response to antifungal therapy. Oral voriconazole was the therapy of choice for six patients (7 mg/kg/dose) and adequate serum levels (≥1 mg/L) were measured in all patients. One child was treated with liposomal amphotericin B (5 mg/kg/day) due to age restrictions (9 months) for using voriconazole.

It is important to note that during the whole period this cluster occurred, the hospital building was being enlarged, counting with an extensive construction area.

All environmental samples and different intravenous preparations in search for sources of *Fusarium* spp. were negative. Healthcare workers who had previous contact with the patients were checked for the presence of any cutaneous or nail lesions suggestive of fungal infections but nothing was found.

**Molecular identification of *Fusarium* isolates**
A total of 16 *Fusarium* spp. clinical isolates were identified to genus level by colony and microscopic characteristics of the isolates. Upon molecular identification, based on *TEF1* and *RPB2* partial genes analysis, all *Fusarium* isolates were found to be members of the *F. oxysporum* species complex. All environmental samples were culture negative.

A phylogenetic tree (Additional file 1: Figure S1) was constructed with a total of 20 sequences for two genes, with three strains from the *Fusarium solani* species complex (FSSC) i.e. *F. falciforme* (NRRL32542), *F. keratoplasticum* (FRC-S2477) and *F. petroliphilum* (NRRL32856) as outgroup. The generated tree was separated into two clades, Clade 1 included all members of the *F. oxysporum* species complex (FOSC) and clade 2 represented the *F. solani* species complex (FSSC), the final result of the identification process was that 16 isolates were confirmed as members of FOSC.

**Typing results by amplified fragment length polymorphism**
All *Fusarium* strains obtained from blood and catheter tips were considered genetically related by AFLP fingerprinting, suggesting that all isolates had a common source. Cluster analysis revealed the presence of two clusters, one with a 95% similarity that includes isolates BRAZIL 1127 (Patient 2 catheter tip culture), 1129 (Patient 2 reservoir culture), 1131 (Patient 2 blood culture) and 1134 (Patient 3 catheter tip culture), and a second one with all other Brazilian isolates that exhibited similarity of 97% (Fig. 1). The reference *F. oxysporum* isolates CBS192.31 and CBS180.29, had a similarity of 90% and 80%, respectively, to the Brazilian isolates.

**Discussion**
In Brazil, invasive fusariosis is the most common cause of systemic mould infections in hematologic cancer patients [4] and has been associated with a poor prognosis [19]. There is a gap in knowledge with regard to the epidemiology of fusariosis in pediatric patients. Most papers...
<table>
<thead>
<tr>
<th>Case</th>
<th>Underlying diseases</th>
<th>HSCT</th>
<th>Age (years)</th>
<th>Gender</th>
<th>Neutropenia</th>
<th>CVC</th>
<th>GMI</th>
<th>Time interval between CVC placement and infection</th>
<th>Chest CT</th>
<th>ECHO</th>
<th>Fundoscopic exam</th>
<th>Therapy</th>
<th>Duration (days)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Solid tumor</td>
<td>Auto</td>
<td>3</td>
<td>Male</td>
<td>Yes</td>
<td>Port-a-cath</td>
<td>Negative</td>
<td>665 days</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Voriconazole</td>
<td>21</td>
<td>Alive</td>
</tr>
<tr>
<td>2</td>
<td>Solid tumor</td>
<td>No</td>
<td>2</td>
<td>Female</td>
<td>No</td>
<td>Port a cath</td>
<td>Negative</td>
<td>89 days</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Voriconazole</td>
<td>21</td>
<td>Alive</td>
</tr>
<tr>
<td>3</td>
<td>Solid tumor</td>
<td>No</td>
<td>1</td>
<td>Male</td>
<td>No</td>
<td>Port a cath</td>
<td>Negative</td>
<td>114 days</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Voriconazole</td>
<td>21</td>
<td>Alive</td>
</tr>
<tr>
<td>4</td>
<td>Solid tumor</td>
<td>No</td>
<td>9 months</td>
<td>Female</td>
<td>No</td>
<td>Port a cath</td>
<td>Negative</td>
<td>125 days</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>L-Ampho B</td>
<td>16</td>
<td>Alive</td>
</tr>
<tr>
<td>5</td>
<td>Solid tumor</td>
<td>Auto</td>
<td>1</td>
<td>Female</td>
<td>No</td>
<td>Port a cath</td>
<td>Negative</td>
<td>112 days</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Voriconazole</td>
<td>21</td>
<td>Alive</td>
</tr>
<tr>
<td>6</td>
<td>Solid tumor</td>
<td>No</td>
<td>2</td>
<td>Female</td>
<td>No</td>
<td>Port a cath</td>
<td>Negative</td>
<td>282 days</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Voriconazole</td>
<td>21</td>
<td>Alive</td>
</tr>
<tr>
<td>7</td>
<td>ALL in remission</td>
<td>No</td>
<td>8</td>
<td>Male</td>
<td>No</td>
<td>PICC</td>
<td>Negative</td>
<td>158 days</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Voriconazole</td>
<td>14</td>
<td>Alive</td>
</tr>
</tbody>
</table>

ALL, acute lymphoblastic leukemia; Auto, autologous; CVC, central venous catheter; PICC, peripherally inserted central catheter; GMI, galactomannan index; ECHO, echocardiography; Chest CT, chest computed tomography; L-Ampho B, liposomal amphotericin B.
represent single case reports, with the exception of two outbreaks that were also documented in Brazilian medical centers and a review paper [20–22]. Information provided by the largest pediatric series of fusariosis published in the medical literature shows that the most common underlying condition was leukemia. Lung, blood and skin were the most commonly reported sites of infection and mortality rates are usually higher than 50% [22].

There is a consensus in the literature that the respiratory tract is the main portal of entry for this fungal infection, followed by skin breakdown due trauma and/or burns [23–31]. Despite some reports suggesting that fusariosis may also be acquired by contamination of a central venous catheter, the real prevalence and the natural history of intravascular catheter related fusariosis remains unclear [32–36].

Velasco and colleagues reported four immunocompromised children between 4 and 12 years, having neuroblastoma (n = 1) or hematologic malignancies (n = 3) who developed catheter-related Fusarium spp. infections without neutropenia. Fungemia was followed by skin lesions in only one patient and there was no clinical or radiological evidence of respiratory tract involvement. All patients survived after catheter removal and treatment with conventional amphotericin B [21].

Recently, Colombo et al. [35] described a case of a 13-year-old boy in Italy diagnosed with ALL readmitted 1 month after the start of chemotherapy due to intermittent fever of unknown origin, without any clinical or radiological evidence of invasive infection. Patient had his Broviac central venous catheter removed and blood cultures taken from the CVC were positive only for F. solani species complex. In addition, scanning electron microscopy of the catheter tip demonstrated the formation of a large mycelium in the catheter lumen that yielded a positive culture of F. solani complex. This finding represents a strong support for the hypothesis that fungemia was related to fungal colonization of the catheter. Fungemia resolved without any evidence of deep-seated infection after prompt CVC removal and therapy with voriconazole.

We report an outbreak of F. oxysporum infection enrolling 6 children with solid cancers and one with ALL in complete remission without persistent neutropenia. Fever was the only clinical manifestation of infection and the trigger to collect blood cultures in all episodes. Patients were carefully examined, and no single event of fungal deep tissue infection was documented. Finally, in the absence of respiratory infection as well as any type of skin breakdown that could be the port of entry, we are convinced that the intravascular catheter was the source of all episodes of F. oxysporum. Indeed, by typing all isolates with AFLP we confirmed our hypothesis that the 7 cases of F. oxysporum were related, and all cultures of catheter tips and reservoirs had similar or identical genotypes to isolates obtained from blood cultures. Because all environmental investigations were negative for the presence of Fusarium spp., we were not able to identify the presumed common source of all infections. On the other hand, we may not exclude the possibility that medical devices were colonized by Fusarium during inappropriate management of intravascular catheters by health care workers or by the contamination of intravascular fluids.

Disseminated fusariosis is a difficult to treat fungal infection with an overall mortality ranging between 50% and 80% mostly due to uncontrolled hematologic malignant disease, prolonged neutropenia and the exposition to corticosteroids [19, 37]. Indeed, during a recent outbreak among children with cancer, fungemia and deep-seated infections due to Fusarium the mortality rate was 50% [20].

In contrast, in the present series, and as documented by previous reports of catheter related fusariosis [21, 33], we observed a complete clinical recovery of all patients after removal of the intravascular catheter and initiation of appropriate antifungal therapy. The good outcome
documented with our patients may be explained also because there was no neutropenia or exposition to corticosteroids at the time they developed fusariosis.

*F. oxysporum* was the etiologic agent responsible for all fungemias documented in the present outbreak. This finding is in accordance with previous reports where seven out ten cases of *Fusarium* spp. fungemias and intravascular catheter related infections were due non-*solani* *Fusarium* species [21, 23, 33–36, 38]. Measures taken to control the outbreak were lowering the level of humidity in the CVC storage room and the implementation of a multidisciplinary quality-improvement intervention, including a central line insertion care bundle, consisting of hand hygiene, maximal sterile barrier use upon insertion and use of chlorhexidine skin disinfection. After the introduction of these actions, no further cases were noted.

In conclusion, *Fusarium* fungemia may be acquired by intravascular catheter colonization without any further deep-seated infections. In case of *Fusarium* outbreaks, especially involving non-*F. solani* species, clinicians should be aware that contamination of central venous catheter may be the potential source of infection.

**Conclusions**

We described 7 episodes of *Fusarium oxysporum* fungemia where we presented strong clinical and laboratory documentation supporting the hypothesis that the portal of entry for all cases of fusariosis was the intravascular central catheter. In case of *Fusarium* outbreaks, especially involving non-*F. solani* species, clinicians should be aware that contamination of central venous catheter may be a potential source. Finally, we added information suggesting that the clinical outcome of catheter related fungemia due to *Fusarium* may be favorable in patients without neutropenia who were submitted to prompt CVC removal and early initiation of antifungal therapy.

**Acknowledgements**

The authors wish to thank the staff of the Laboratório Especial de Micologia-UNIFESP as well as the clinical teams of the Oncology Pediatric Institute (IOP-GRAACC) involved for all their commitment in managing the outbreak.

**Funding**

No funding.

**Availability of data and materials**

Please contact author for data requests.

**Authors’ contributions**

FC and ALC performed epidemiological data analysis and initial draft preparation. FC, AP, MLA, V, and AS took care of patients and were involved in outbreak control. SSG, FH, and AM, performed molecular studies. JFM and ALC provided expert advice and methodology, FC, JFM, and ALC finalized the draft. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the local institutional review board with approval IRB number 1.939.913.

**Consent for publication**

Not applicable.

**Competing interests**

FC received educational grants from Pfizer, United Medical and Astellas. ALC received educational grants from Pfizer, Gilead, United Medical and Astellas, and funding for research from Pfizer and Astellas. JFM received grants from Astellas, Basilea and Merck. He has been a consultant to Astellas, Basilea and Merck and received speaker’s fees from Merck, United Medical and Gilead. All other authors no conflict of interest.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Oncology Pediatric Institute (IOP-GRAACC), Escola Paulista de Medicina, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil. 2. Department of Pediatrics, Escola Paulista de Medicina, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil. 3. Division of Infectious Diseases, Escola Paulista de Medicina, Federal University of Sao Paulo (UNIFESP), Rua Pedro de Toledo, 669 e 5°-andar, Sao Paulo CEP 04039-032, Brazil. 4. Western Fungal Biodiversity Centre, Utrecht, The Netherlands. 5. Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands. 6. Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital (CWZ), Nijmegen, The Netherlands.

**Received:** 11 July 2017 **Accepted:** 24 August 2017 **Published online:** 07 September 2017

**References**
